Maastricht University Medical Center
Dartbac
The resistance of bacteria to antibiotics (AntiMicrobial Resistance; AMR) is a rapidly increasing problem with devastating consequences on quality of life worldwide. AMR is associated with unfavourable clinical outcomes that can result in many deaths and skyrocketing healthcare costs.
DARTBAC was one of the largest, winning proposals within the NWA-ORC-call in 2020 and will develop new antimicrobial technologies from a material perspective. These technologies will not be based on antibiotics to target infection, but will instead focus on prevention and eradication on implant surfaces in hard and soft tissues.
Applicant
- Maastricht University Medical Centre
Consortium
- University Maastricht
- University Medical Centre Groningen
- Eindhoven University of Technology
- Delft University of Technology
- University Medical Centre Utrecht
- University of Amsterdam
- Amsterdam University Medical Center
- Leiden University
- National Institute for Public Health and the Environment
- Braun Aesculap
- BiosparQ
- Bonalive Biomaterials ltd
- CAM Bioceramics B.V.
- DSM Biomedical
- MadamTherapeutics
- OS-1
- PCI Biotech
- ReumaNederland
- Zorginnovatie Nederland B.V.
